Deal done with Medtronic. Real coup to do a deal with such a massive US company. US$71.4 billion market cap. This is a big deal. Medtronic only got the rights to the heart applications. All the orthopedic stuff, XBL retain rights over, so... Expect:
1. Roadshow to major analysts and instos. (MD is ex Metabolic Circadian and Axon so has contacts and cred)
2. Deals on the orthopedic applications.
3. Potential spin-off company
This thing is ridiculously cheap given its potential and given independent validation of its technology by MEd.
- Forums
- ASX - By Stock
- XBL
- exclusive negotiating period almost over
XBL
xceed biotechnology ltd